This site contains promotional material

Prescribing Information SmPC

Unlock the
Future for
Children
with MLD

Listen. Test. Refer.

Libmeldy: Ex vivo autologous HSC gene therapy for early-onset MLD

Libmeldy is an autologous haematopoietic stem cell (HSC) gene therapy product for early-onset MLD made specifically for each patient using the patient’s own blood stem cells.1

See indication
What is MLD?

What is MLD?

Metachromatic leukodystrophy (MLD) is a rare, inherited, neurometabolic disease that causes rapid and progressive demyelination and neurodegeneration, leading to severe neurological disability and death.2 MLD is caused by mutations in the arylsulfatase A (ARSA) gene which lead to ARSA enzyme deficiency.1

See disease info
How can Libmeldy help?

How can Libmeldy help?

Libmeldy is indicated for the treatment of children with early-onset MLD. CD34+ cells are transduced ex vivo with a lentiviral vector encoding ARSA cDNA. It is an autologous gene therapy, meaning a patient’s own stem cells are genetically corrected by inserting a functional copy of the ARSA gene and these are returned to their body.1

See full indication

Abbreviations
ARSA, arylsulfatase A; cDNA, complementary DNA; HSC, haematopoietic stem cell; MLD, metachromatic leukodystrophy

For any medical questions, please contact medinfo@orchard-tx.com

▼ This medicinal product is subject to additional monitoring.
Healthcare professionals are asked to report any suspected adverse events. Further information about local reporting details can be found in Section 4.8 of the Summary of Product Characteristics.

Please also report any adverse events to Orchard Therapeutics at: drugsafety@orchard-tx.com

References

  1. Libmeldy, Summary of Product Characteristics. March 2021
  2. Rosenberg JB, et al. J Neurosci Res 2016; 94(11): 1169-1179.

Welcome

This site is developed and hosted by Orchard Therapeutics ltd. UK and intended for Health Care Professionals from countries where the product registration by the EMA is accepted.

IMPORTANT: Product information on this website is based on the European Summary of Product Characteristics (EU SmPC)
This site is not intended for US healthcare professionals.

If you are not a European healthcare professional, please click here.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions according to their national guidelines.